Literature DB >> 15234109

G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.

M Orth1, S J Tabrizi, C Tomlinson, K Messmer, L V P Korlipara, A H V Schapira, J M Cooper.   

Abstract

Alpha synuclein protein may play an important role in familial and sporadic Parkinson's disease pathology. We have induced G209A mutant or wild-type alpha-synuclein expression in stable HEK293 cell models to determine if this influences markers of oxidative stress and damage under normal conditions or in the presence of dopamine or paraquat. Induced wild-type or mutant alpha-synuclein expression alone had no effect upon levels of oxidative stress or damage, as measured by glutathione levels or aconitase activity. Both wild-type and mutant alpha-synuclein expression decreased the oxidative damage induced by paraquat, although the protection was less marked with mutant alpha-synuclein expression. This suggests that alpha-synuclein expression may either have anti-oxidant properties or may upregulate cellular antioxidant levels, a function that was diminished by the G209A mutation. However, mutant but not wild-type alpha-synuclein expression specifically enhanced dopamine associated oxidative damage. Non-expressing cells treated with reserpine to inhibit the vesicular monoamine compartmentalisation produced similar results. However, consistent with the hypothesis that mutant alpha-synuclein disrupts vesicular dopamine compartmentalization, this effect was diminished in cells expressing mutant alpha-synuclein. This may result in increased dopamine metabolism and cause selective oxidative damage to dopaminergic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234109     DOI: 10.1016/j.neuint.2004.03.029

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  10 in total

Review 1.  Agrochemicals, α-synuclein, and Parkinson's disease.

Authors:  Blanca A Silva; Leonid Breydo; Anthony L Fink; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-08-30       Impact factor: 5.590

Review 2.  The role of oxidative stress in Parkinson's disease.

Authors:  Vera Dias; Eunsung Junn; M Maral Mouradian
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

3.  Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo.

Authors:  Shankar J Chinta; Jyothi K Mallajosyula; Anand Rane; Julie K Andersen
Journal:  Neurosci Lett       Date:  2010-09-29       Impact factor: 3.046

4.  Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells.

Authors:  Marco Bisaglia; Elisa Greggio; Dragan Maric; David W Miller; Mark R Cookson; Luigi Bubacco
Journal:  BMC Neurosci       Date:  2010-03-25       Impact factor: 3.288

Review 5.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

Review 6.  Oxidative stress in genetic mouse models of Parkinson's disease.

Authors:  Mustafa Varçin; Eduard Bentea; Yvette Michotte; Sophie Sarre
Journal:  Oxid Med Cell Longev       Date:  2012-07-08       Impact factor: 6.543

Review 7.  Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF.

Authors:  Roman Fischer; Olaf Maier
Journal:  Oxid Med Cell Longev       Date:  2015-03-05       Impact factor: 6.543

Review 8.  Multiple system atrophy: genetic or epigenetic?

Authors:  Edith Sturm; Nadia Stefanova
Journal:  Exp Neurobiol       Date:  2014-12-12       Impact factor: 3.261

Review 9.  Extracellular Vesicles and Damage-Associated Molecular Patterns: A Pandora's Box in Health and Disease.

Authors:  Anna Picca; Flora Guerra; Riccardo Calvani; Hélio José Coelho-Júnior; Francesco Landi; Roberto Bernabei; Roberta Romano; Cecilia Bucci; Emanuele Marzetti
Journal:  Front Immunol       Date:  2020-11-16       Impact factor: 7.561

Review 10.  α-Synuclein and mitochondrial dysfunction in Parkinson's disease.

Authors:  Stephen Mullin; Anthony Schapira
Journal:  Mol Neurobiol       Date:  2013-01-30       Impact factor: 5.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.